TABLE 2.
Twelve-month Outcomes Compared by Every 4- and Every 6-Week Ustekinumab Intervals
| Outcomes | Ustekinumab Every 4 Weeks | Ustekinumab Every 6 Weeks | P b |
|---|---|---|---|
| Corticosteroid-free remission (HBI <5)a, %, n = 42, n = 33 | 54.8 | 54.6 | 0.99 |
| Change to new biologic, %, n = 44, n = 40 | 18.2 | 7.5 | 0.15 |
| Clinical response (∆ HBI ≥3)c, %, n = 38, n = 29 | 60.5 | 58.6 | 0.24 |
| Endoscopic improvement, %, n = 27, n = 19 | 63.0 | 63.2 | 0.99 |
| Improvement in CT or MRI abdomen, %, n = 29, n = 14 | 41.4 | 35.7 | 0.72 |
| Improvement in perianal disease, %, n = 24, n = 26 | 16.7 | 7.7 | 0.33 |
| Start corticosteroids, %, n = 45, n = 49 | 15.6 | 15.0 | 0.94 |
| IBD surgery, %, n = 44, n = 40 | 11.4 | 5.0 | 0.29 |
| IBD hospitalization, %, n = 45, n = 40 | 17.8 | 7.5 | 0.16 |
| Reduction in CRP by 25%, %, n = 45, n = 39 | 40.0 | 53.9 | 0.20 |
| Normalization of elevated CRP, %, n = 38, n = 28 | 23.7 | 7.1 | 0.08 |
| Normalization of elevated fecal calprotectin, %, n = 14, n = 3 | 7.1 | 33.3 | 0.20 |
aExcludes patients with HBI <5 and no corticosteroid use at time of intensification
bCalculated by Student ttest or Pearson χ 2 test
cExcludes patients with HBI ≤5 at time of intensification